Ischaemic stroke has become one of the leading causes of death and disability in the world. Protease activated receptors (PARs, PAR-1 to PAR-4) belong to G protein coupled receptors that can be self-activated by tethered ligands (TL) revealed through proteolytic cleavage. Based on these TL, many activating peptides (APs) and antagonists have been synthesized to investigate PARs actions. / In the present study, the roles of PARs were examined in two models of ischaemic stroke. For the in vivo model, transient middle cerebral artery occlusion (tMCAO) was performed to establish cerebral ischaemia in rats. For the in vitro model, oxygen and glucose deprivation (OGD) was used to mimic an ischaemia insult in primary cultured rat embryonic cortical neurones. / Western blot studies showed that expressions of PAR-1 and PAR-2 were increased in the rat ischaemic brain cortex, whereas PAR-1 was reduced in the rat cortical neurones subjected to OGD. Pretreatments of PAR-1 AP (SFLLRN-NH₂) and PAR-2 AP (SLIGRL-NH₂) produced significant protection against ischaemia-induced damage. Pretreatment of PAR-3 AP (SFNGGP-NH₂) only improved ischaemic symptoms in in vivo but not in in vitro model. When treated after ischaemia, only PAR-1 AP produced significant reductions on ischaemia-induced damage. Protective actions of PAR-1 and PAR-2 APs were inhibited by PAR-1 antagonist (BMS-200261) and PAR-2 antagonist (ENMD-1068) respectively, but PAR-1 antagonist did not affect posttreatment effects of PAR-1 AP in in vitro model. Pre- and posttreatments of thrombin, and pretreatment of trypsin also protected ischaemia-induced damage in the two models. / PAR-1 AP produced marked increase in the activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and ratio of bcl-2/bax, but reduced contents of reactive oxygen species (ROS), nitric oxide (NO) and malondialdehyde (MDA) in both ipsilateral ischaemic brain cortices and in rat cortical neurones subjected to OGD. In the in vitro model, PAR-1 AP greatly decreased caspase-3 activity and TUNEL positive cells, while markedly increased mitochondrial membrane potential (MMP). All these protective actions were inhibited by its antagonist, which suggests it was mediated via activation of PAR-1. / In MCA isolated from normal and ischameic rats, PAR-2 AP and trypsin produced vasodilatation while PAR-3 AP elicited vasoconstriction. However, another PAR-3 AP had no effect in the two types of MCA. A high concentration of PAR-1 AP relaxed MCA isolated form ischaemic rats, and it was not inhibited by a PAR-1 antagonist. The vasodilator action of PAR-2 AP was inhibited by one of two PAR-2 antagonists tested. The vasodilator actions induced by PAR-1 and PAR-2 APs involved NO production since L-NAME was effective in inhibiting their actions. / In conclusion, PAR-1 AP was found to be the most efficacious in protecting the brain from ischaemia-induced damage when administered either before or after ischaemia insults. The protective actions were likely to be attributed to its anti-oxidant properties in the ischaemic brain that reduced apoptosis of brain cells. Therefore, PAR-1 was identified as a promising target for development of novel prophylactic and therapeutic treatments of ischaemic brain disease. / 缺血性腦中風已經成為全世界導致死亡和殘疾的最主要的疾病之一。蛋白酶激活受體（PARs, PAR-1 to PAR-4）屬於G蛋白偶聯受體並且可以通過蛋白水解生成系鎖配體（TL）從而作用於受體本身而激活信號通路。根據TL的序列已經合成了很多激活肽和拮抗劑，它們可以作為有價值的工具藥進行PAR的作用研究。 / 當前，PAR的作用在兩個缺血性腦中風模型中進行研究。體內模型是通過大鼠大腦中動脈阻塞手術而建立；體外模型是通過對大鼠胚胎大腦皮層神經元進行氧糖剝奪模擬缺血性損傷。 / 蛋白質印跡法的實驗表明PAR-1和PAR-2的表達在缺血側大腦皮層中有所增多，而PAR-1在氧糖剝奪的大鼠皮層神經元中表達卻有所降低。預處理PAR-1（SFLLRN-NH₂）和PAR-2（SLIGRL-NH₂）的激活肽顯著改善了缺血導致的損傷。預處理PAR-3激活肽（SFNGGP-NH₂）僅僅改善了體內缺血症狀，卻對體外缺血模型沒有效果。然而，當這些激活肽在缺血后給予的時候，只有PAR-1的激活肽顯著改善了缺血損傷。PAR-1的拮抗劑（BMS-200261）和PAR-2的拮抗劑（ENMD-1068）抑制了PAR-1和PAR-2激活肽的保護作用，但是體外實驗後處理PAR-1激活肽的保護作用卻未收影響。預處理及後處理凝血酶，預處理胰酶都在這兩個模型中顯示出保護缺血性損傷的作用。 / PAR-1激活肽在缺血同側大腦皮層以及經受氧糖剝奪的大鼠皮層神經元中，顯著提高了超氧化物歧化酶（SOD）、過氧化氫酶（CAT）、谷胱甘肽過氧化物酶（GSH-Px）的活力以及bcl-2/bax的比例，同時顯著降低了活性氧自由基（ROS）、一氧化氮（NO）以及丙二醛（MDA）的含量。在體外模型中，PAR-1激活肽還顯著降低了caspase-3的活力以及TUNEL陽性細胞的比例，同時顯著提高了線粒體膜電位（MMP）。所有這些作用都可以被拮抗劑抑制，說明PAR-1激活肽的保護作用是通過激活PAR-1介導的。 / 不管是從正常還是缺血的大鼠中分離出來的大腦中動脈，PAR-2激活肽和胰酶都可以使之舒張，PAR-3激活肽卻對其有收縮作用。然而，另外一種PAR-3激活肽卻未顯現出對血管活性的影響。高劑量的PAR-1激活肽只可以在分離于缺血大鼠的大腦中動脈中引起舒張，但此作用不能被其拮抗劑所抑制。PAR-2激活肽導致的血管舒張只可以被檢測的兩個拮抗劑中的其中一個所抑制。PAR-1和PAR-2激活肽引起的血管舒張與NO的產生有關，因為L-NAME可以有效抑制它們的作用。 / 總之，不管是預處理還是後處理的給藥方式，PAR-1的激活肽在保護大腦的缺血性損傷中都是最有效果的。保護作用可能可以歸因于其抗氧化以及抗凋亡的特性。所以，PAR-1是研究防治缺血性腦疾病的發展中富有希望的一個靶點。 / Zhen, Xia. / Thesis Ph.D. Chinese University of Hong Kong 2014. / Includes bibliographical references (leaves 194-206). / Abstracts also in Chinese. / Title from PDF title page (viewed on 11, October, 2016). / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only.

Objetivo: Analisar e descrever o perfil de expressão das proteínas relacionadas ao mecanismo de apoptose (PARP e AIF), e o perfil de expressão gênica sérica do microRNA-9 relacionado ao mecanismo de apoptose, em ratos submetidos à isquemia cerebral focal por oclusão da ACM por 90 minutos, seguida de reperfusão de 48horas, associado ou não com modelo de alcoolismo crônico. Métodos: Foram utilizados 20 ratos Wistar adultos, subdivididos em 4 grupos experimentais: grupo controle (C): animais submetidos apenas à anestesia; grupo isquêmico (I): animais submetidos à isquemia cerebral focal por 90 minutos seguido por reperfusão de 48 horas; grupo alcoolizado (A): animais que receberam diariamente álcool etílico absoluto diluído a 20% em água durante quatro semanas; e, grupo isquêmico e alcoolizado (IA): animais submetidos ao mesmo tratamento do grupo A e que, após quatro semanas foram submetidos à isquemia cerebral focal durante 90 minutos, seguido por reperfusão de 48 horas. As amostras do encéfalo coletadas foram processadas para a análise imunohistoquímica (para a expressão protéica de PARP-1 e AIF); e o sangue da artéria ventral da cauda foi coletado para a análise da expressão gênica do miRNA-9, relacionada ao mecanismo de apoptose, pela técnica de PCR em tempo real. Resultados: A comparação entre os grupos identificou uma redução da expressão proteica de PARP-1 nos animais do grupo AI quando comparado com os demais. Foi observada marcação positiva nuclear para a proteína AIF somente no grupo IA. Não houve diferença estatisticamente significante da expressão sérica do miRNA-9 entre os grupos. Conclusão: O modelo proposto, pode não ter sido suficiente para promover a ativação de AIF nos grupos C, A e I e desta forma, a apoptose celular por essa via analisada. A expressão proteica de PARP-1 no grupo A, associado com a expressão nula de AIF, indica um efeito neuroprotetor do etanol neste grupo. A redução da expressão proteica de PARP-1 não afetou sua atividade enzimática, proporcionando, mesmo em baixas concentrações, ativação de AIF no grupo IA. A expressão de PARP- 1 no grupo I, associada a expressão nula de AIF indica que o modelo de isquemia possivelmente gerou leves danos no DNA o que estimulou a ativação de PARP-1 somente em níveis suficientes para promover a reparação do DNA e não a ativação do processo de apoptose pela translocação de AIF. A expressão gênica sérica do miRNA- 9 observada indicou que a mesma foi suprimida quando exposta a mecanismos de estresse (alcoolismo, isquemia e a associação dos mesmos). A correlação do miRNA-9 com a expressão proteica de PARP-1 e AIF, indicou um aspecto protetor da baixa regulação do miRNA-9 tanto em animais alcoolizados como em animais isquêmicos. O grupo IA apresentou uma tendência a baixa expressão do miRNA-9, baixa expressão de PARP-1 e alta expressão de AIF, indicando que a associação álcool e isquemia tenha interferido no efeito protetor do miRNA-9 visto nos demais grupos / Aim: To analyze and describe the expression profile of proteins related to apoptosis mechanism (PARP and AIF), and profile of gene expression of miRNA-9 related to apoptosis mechanism in rats submitted to focal cerebral ischemia by occlusion of the CMA for 90 minutes, followed by 48 hours of reperfusion, associated or without associated to chronic alcoholism model. Methods: 20 adult Wistar rats were used, divided into 4 groups: control group (C): animals submitted only to anesthesia; Ischemic group (I): animals subjected to focal cerebral ischemia for 90 minutes followed by 48 hours of reperfusion; alcoholic group (A): animals that received daily solution of 20% of absolute ethyl alcohol diluted in water during four weeks; and ischemic group and alcoholized (IA): Animals subjected to the same treatment group A and after four weeks were subjected to focal cerebral ischemia for 90 minutes followed by 48 hours of reperfusion. The brain samples were collected and processed for immunohistochemical analysis (for protein expression - PARP-1 and AIF); and the blood from ventral artery of tail was collected for the analysis, by PCR in real time, of gene expression of miRNA-9 related to the mechanism of apoptosis. Results: The comparison between the groups identified a decrease in protein expression (PARP-1) in animals from IA group compared to others groups. Nuclear positive staining was observed for the AIF protein only in the IA group. There was no significant difference in serum expression of miRNA-9 between the groups. Conclusion: The proposed model may not have been sufficient to promote the activation of AIF in groups C, A and I, and thus the apoptosis analyzed in this way. Protein expression of PARP-1 in group A associated with a null expression of AIF, indicate a neuroprotective effect of ethanol in this group. The reduction of protein expression PARP-1 did not affect its enzymatic activity, providing even at low concentrations, activation AIF in IA group. The expression of PARP-1 in group I associated with null expression of AIF showed that model of ischemia, possibly, promoted light damage in DNA which stimulated PARP-1 activation just in sufficient levels to promote DNA repair, and without activation of apoptosis by translocation of AIF. The gene expression of miRNA-9 indicated that it was suppressed when exposed to mechanical stress (alcoholism, ischemia and combination thereof). The correlation of miRNA-9 with the protein expression (PARP-1 and AIF), indicated a protective aspect of downregulation of the miRNA-9 in both animals drunk as ischemic animals. IA group showed a trend to low expression of miRNA-9 and PARP- 1, in other hand an overexpression of AIF, indicating that the association between alcohol and ischemia interfered in protective effect of miRNA-9 seen in the other groups

Release of glutamate in cerebral ischemia results in an excitotoxic reaction in the central nervous system resulting in neuronal cell loss. Providing neuronal protection via N‐methyl D‐asparate (NMDA) receptor blockade in response to cerebral ischemia may result in preservation of function following ischemia. The present study was designed to test compound AT010, an NMDA signaling antagonist, on behavioral compensation and infarct size in a cerebral ischemia model in the rat. Animals were surgically implanted with a filament via the external carotid artery, providing an occlusion of he medial cerebral artery for 60 min. Approximately 30‐45 minutes prior to surgery, the compound AT010 (3uM or 10uM) or saline was iv administered at 1% of body weight. All animals were behaviorally tested on behavioral tasks that analyzed postural reflex, limb placement, righting reflex, adhesive removal, and behavioral motor function at 3, 7, and 14 days post‐ischemia. In addition, animals were tested on the Morris water maze, a spatial memory task 28 days post‐ischemia. Regardless of dose, composite neurological scores for all motor and sensory tasks were higher for animals given AT010 compared to saline at 7 and 14 days post‐ ischemia. Water maze results revealed significant improvement of animals administered the higher dose of AT010 (10uM) on acquisition and probe trial performance, although no effect was revealed for the lower dose (3 uM). Finally, analysis of brain tissue samples revealed no significant effect on infarct size. These results indicate that compensation occurred throughout the undamaged brain areas, likely through synaptic communication changes as a result of drug treatment.

Eukaryotic cells are unique in their ability to form complex multicellular organisms giving rise to distinct physiological systems. However, the ability for such complexity to evolve likely stems from an early event in which endosymbiosis of an aerobic prokaryote by a eukaryotic precursor gave rise to the eukaryotic organelle we now know as mitochondria. Mitochondria are colloquially known as the “power house” of the cell due to their ability to produce ATP through oxidative phosphorylation, but perform numerous other vital functions within the cell including sequestration of cytosolic Ca2+, production and sequestration of reactive oxygen species (ROS), and initiation of various forms of cell death. Mitochondria are especially important in neurons given their high demand for ATP and the importance of Ca2+ signaling in neuron excitability and development. Neurons are highly compartmentalized and plastic cells requiring the ability to control energy supply and Ca2+ signaling locally within given specialized structures such as dendritic spines or synaptic boutons. Therefore, mitochondria must be able to localize to particular sub-cellular locales and respond functionally to signaling occurring in that environment. Mitochondrial transport and function are heavily dependent upon the ability of mitochondria to undergo opposing and reversible fission and fusion events. Mitochondrial fission and fusion are themselves regulated by GTPase enzymes which physically catalyze constriction and fusion of the mitochondrial membranes. Mutations in mitochondrial fission and fusion enzymes specifically cause neurological disease in humans and recent work has illustrated the necessity of a proper balance of mitochondrial fission in neuron development, survival, and plasticity. Despite recognizing the importance of mitochondrial fission and fusion in neuron survival, development, and function we lack a concrete understanding of how changes in the equilibrium of fission and fusion impact these processes in vivo. In this thesis we investigate how promoting or inhibiting mitochondrial fission, through phosphoregulation of the mitochondrial fission enzyme Dynamin related protein 1 (Drp1) at mitochondria, impacts neuron survival and memory in vivo. We find that inhibiting phosphorylation of Drp1 at Serine 656 (S656) at the mitochondria, through deletion of a mitochondrial targeted A kinase anchoring protein (AKAP) known as AKAP1 in mice, increases cerebral infarct volume following transient occlusion of the mid-cerebral artery. Oppositely, promoting phosphorylation of Drp1-S656 at the mitochondria, through deletion of the PP2A regulatory subunit Bβ2 which localizes the PP2A heterotrimer to mitochondria, decreases cerebral infarct volume following occlusion of the mid-cerebral artery. Mechanistic in vitro studies in primary neurons reveal these effects are dependent upon the phosphorylation state of Drp1-S656 and likely due to altered mitochondrial respiratory capacity, ROS production, and Ca2+ homeostasis. Interestingly, we also observe improved hippocampal dependent memory in mice in which AKAP1 has been deleted which also appears dependent upon the phosphorylation state of Drp1-S656 and Ca2+ homeostasis. Ultimately, these findings provide insight into how phosphoregulation of Drp1 at the mitochondria alters neuron survival and function through shifting the mitochondrial fission/fusion equilibrium and consequently mitochondrial function.

Subsequent to an hypoxic-ischaemic (HI)-insult a multi-faceted complex cascade of events occurs that ultimately results in cellular and neurological impairments within cortical and sub-cortical central nervous system (CNS) regions. In the present studies a modified �Levine� rat-pup model of HI (left carotid artery ligation + 1 hour global hypoxia on post-natal day (PND) 26) was employed to assess the neuroprotective properties of clomethiazole (CMZ; a γ-aminobutyric acid (GABA)A receptor agonist). In this study, histological and electrophysiological paradigms were used to assess the long-term neuroprotective properties of CMZ (414mg/kg/day via mini-pumps). Key enzymes involved in inflammation, namely nitric oxide synthase (NOS) and arginase, were also examined to assess other potential CMZ mechanisms. Assessments were carried out 3- and 90-days post-HI, with extensive ipsilateral CNS lesions evident at a gross histological level, at both the early and long-term stages, with CMZ significantly decreasing the lesion size at 3- and 90-days (P<0.01; P<0.05). Evoked field potential analyses were used to assess hippocampal CA1 neuronal activity ex vivo. Electrophysiological measurements contralateral to the occlusion revealed impaired neuronal function following HI relative to short- and long-term controls (P<0.001, 3- and 14-days; P<0.01, 90-days), with CMZ providing near complete protection (P<0.001 at 3- and 14-days; P<0.01 at 90-days). Both inducible NOS (iNOS) and arginase activities were significantly increased at 3-days (P<0.01), with arginase activity remaining elevated at 90-days post-HI (P<0.05) ipsilaterally. CMZ suppressed the HI-induced increase in iNOS and arginase activities (P<0.001; P<0.05). These data provide evidence of long-term functional neuroprotection afforded by CMZ in a model of HI-induced neurodegeneration. In addition, under conditions of HI, functional deficits were not restricted to the ipsilateral hemisphere and were due, at least in part, to changes in the activity of NOS and arginase. Underlying mitochondrial dysfunction is eminently present in many neuropathological conditions. The full extent of mitochondrial dysfunction in cortical, hippocampal and cerebellar tissues was assessed following HI. Assessment of mitochondrial FAD-linked respiration at both 1- and 3-days post-HI revealed a significant decrease in activity from ipsilateral cortical and hippocampal regions (P<0.001). In addition, significant changes in respiratory function were also evident in contralateral regions and cerebellum, 3-days post-HI (P<0.05). Assessment of the mitochondrial electron transport chain (complexes I-V) and mitochondrial markers of integrity (citrate synthase) and oxidative stress (aconitase) confirmed ipsilateral mitochondrial impairment following HI. Complexes I, II-III, V and citrate synthase were also impaired, in contralateral regions and cerebellum, 3-days post-HI. CMZ treatment provided significant protection to all mitochondrial aspects of neuronal tissue assessed. This study provides evidence of the full extent of mitochondrial damage following an HI-insult and may contribute, in part, to the impairment seen contralaterally. In addition, protection afforded by CMZ extends to preservation of mitochondrial function and integrity. Cerebral ischaemia-induced angiogenesis has been shown within and around infarcted regions and may contribute to a more favourable neurological outcome. The level of angiogenesis was examined using platelet endothelial cell adhesion molecule-1 (PECAM-1 / CD31). CD31 immunolabelling 7-days post-HI revealed a significant increase in angiogenesis compared with non-intervention controls (P<0.001). Treatment with CMZ decreased the level of angiogenesis compared to HI + saline (P<0.001) back to non-intervention control levels. Conversely, N[omega]-nitro-L-arginine methyl ester (L-NAME) treatment (5mg/kg/day) exacerbated the ischaemic lesion (P<0.001) and resulted in a marked decrease in angiogenesis compared to non-intervention controls (P<0.001). The extent of cerebral infarction in these studies is dependent on the level of NOS activity with CMZ increasing total NOS levels compared to HI + saline, while L-NAME halted the HI-induce increase in total NOS activity (P<0.001). These results show for the first time, that angiogenesis may be used as an assessment of neurodegeneration / neuroprotection in pathologies of cerebral ischaemia and are directly correlated with changes in NOS activity. These studies have therefore shown that following HI, damage also occurs contralateral to the occlusion, and is not restricted to the ipsilateral hemisphere. In addition, the neuroprotective effects of CMZ have been shown to extend out to 90-days post-HI, whereby significant protection to CA1 neuronal activity was seen. These studies also provide in vivo evidence that CMZ may also afford neuroprotection via anti-inflammatory pathways, as evidenced by a decrease in iNOS and arginase activities. Furthermore, these studies have also show evidence that angiogenesis (CD31) can be used as a diagnostic tool to assess neuroprotection / neurodegeneration.

Thesis (Ph. D.)--Ohio State University, 2006. / Full text release at OhioLINK's ETD Center delayed at author's request.

Thesis (Ph. D.)--Rutgers University, 2009. / "Graduate Program in Physiology and Integrative Biology." Includes bibliographical references (p. 95-114).

Thesis (MD (Anaesthesiology))--University of Pretoria, 2003. / Includes bibliographical references.

Ischaemic stroke is a complex disorder with many different aetiologies, but previous studies of stroke often did not differentiate aetiological subtypes of ischaemic stroke. However, different stroke subtypes may have different risk factors, and to target preventive treatments more effectively, we need to understand these associations. I studied the association of established vascular risk factors with different aetiological stroke subtypes in population-based cohorts of stroke patients. I studied Diffusion Weighted Magnetic Resonance Imaging (DWI) in patients with subacute minor stroke and TIA to determine whether DWI may be a useful addition to the management of such patients, and whether it may be a useful tool in future epidemiological studies of stroke. To determine whether carotid anatomy may be a risk factor for large vessel atheroma I studied angiographical data from the European Carotid Surgery Trial. My main findings are that the prevalence of risk factors differs between stroke subtypes. It also differs between hospitalised and non-hospitalised patients, highlighting that risk factor studies should be performed in population-based cohorts. Analysis of family history data suggests that future genetic studies may best be targeted at non-cardioembolic stroke and at younger patients, and that genetic studies of hypertension may help to unravel some of the genetic factors contributing to stroke risk. DWI is sensitive in subacute minor stroke, and inter- and intra-observer reproducibility are high. DWI frequently adds useful information and may influence patient management. More widespread use of DWI in patients with subacute stroke and TIA should be considered, and DWI may also be a useful tool in future epidemiological studies of stroke. Carotid anatomy varies considerably between individuals, is very asymmetrical within individuals, and it differs between men and women. These findings may partly explain differences in plaque development between individuals, asymmetrical plaque formation within individuals, and sex differences in the distribution of carotid plaque and in the prevalence of carotid atheroma in the general population. Carotid anatomy may be a risk factor for local plaque development. Although not amenable to treatment, knowing which anatomical configuration is associated with atheroma formation could help to identify high-risk individuals in whom other risk factors should be treated aggressively.

Subsequent to an hypoxic-ischaemic (HI)-insult a multi-faceted complex cascade of events occurs that ultimately results in cellular and neurological impairments within cortical and sub-cortical central nervous system (CNS) regions. In the present studies a modified �Levine� rat-pup model of HI (left carotid artery ligation + 1 hour global hypoxia on post-natal day (PND) 26) was employed to assess the neuroprotective properties of clomethiazole (CMZ; a γ-aminobutyric acid (GABA)A receptor agonist). In this study, histological and electrophysiological paradigms were used to assess the long-term neuroprotective properties of CMZ (414mg/kg/day via mini-pumps). Key enzymes involved in inflammation, namely nitric oxide synthase (NOS) and arginase, were also examined to assess other potential CMZ mechanisms. Assessments were carried out 3- and 90-days post-HI, with extensive ipsilateral CNS lesions evident at a gross histological level, at both the early and long-term stages, with CMZ significantly decreasing the lesion size at 3- and 90-days (P<0.01; P<0.05). Evoked field potential analyses were used to assess hippocampal CA1 neuronal activity ex vivo. Electrophysiological measurements contralateral to the occlusion revealed impaired neuronal function following HI relative to short- and long-term controls (P<0.001, 3- and 14-days; P<0.01, 90-days), with CMZ providing near complete protection (P<0.001 at 3- and 14-days; P<0.01 at 90-days). Both inducible NOS (iNOS) and arginase activities were significantly increased at 3-days (P<0.01), with arginase activity remaining elevated at 90-days post-HI (P<0.05) ipsilaterally. CMZ suppressed the HI-induced increase in iNOS and arginase activities (P<0.001; P<0.05). These data provide evidence of long-term functional neuroprotection afforded by CMZ in a model of HI-induced neurodegeneration. In addition, under conditions of HI, functional deficits were not restricted to the ipsilateral hemisphere and were due, at least in part, to changes in the activity of NOS and arginase. Underlying mitochondrial dysfunction is eminently present in many neuropathological conditions. The full extent of mitochondrial dysfunction in cortical, hippocampal and cerebellar tissues was assessed following HI. Assessment of mitochondrial FAD-linked respiration at both 1- and 3-days post-HI revealed a significant decrease in activity from ipsilateral cortical and hippocampal regions (P<0.001). In addition, significant changes in respiratory function were also evident in contralateral regions and cerebellum, 3-days post-HI (P<0.05). Assessment of the mitochondrial electron transport chain (complexes I-V) and mitochondrial markers of integrity (citrate synthase) and oxidative stress (aconitase) confirmed ipsilateral mitochondrial impairment following HI. Complexes I, II-III, V and citrate synthase were also impaired, in contralateral regions and cerebellum, 3-days post-HI. CMZ treatment provided significant protection to all mitochondrial aspects of neuronal tissue assessed. This study provides evidence of the full extent of mitochondrial damage following an HI-insult and may contribute, in part, to the impairment seen contralaterally. In addition, protection afforded by CMZ extends to preservation of mitochondrial function and integrity. Cerebral ischaemia-induced angiogenesis has been shown within and around infarcted regions and may contribute to a more favourable neurological outcome. The level of angiogenesis was examined using platelet endothelial cell adhesion molecule-1 (PECAM-1 / CD31). CD31 immunolabelling 7-days post-HI revealed a significant increase in angiogenesis compared with non-intervention controls (P<0.001). Treatment with CMZ decreased the level of angiogenesis compared to HI + saline (P<0.001) back to non-intervention control levels. Conversely, N[omega]-nitro-L-arginine methyl ester (L-NAME) treatment (5mg/kg/day) exacerbated the ischaemic lesion (P<0.001) and resulted in a marked decrease in angiogenesis compared to non-intervention controls (P<0.001). The extent of cerebral infarction in these studies is dependent on the level of NOS activity with CMZ increasing total NOS levels compared to HI + saline, while L-NAME halted the HI-induce increase in total NOS activity (P<0.001). These results show for the first time, that angiogenesis may be used as an assessment of neurodegeneration / neuroprotection in pathologies of cerebral ischaemia and are directly correlated with changes in NOS activity. These studies have therefore shown that following HI, damage also occurs contralateral to the occlusion, and is not restricted to the ipsilateral hemisphere. In addition, the neuroprotective effects of CMZ have been shown to extend out to 90-days post-HI, whereby significant protection to CA1 neuronal activity was seen. These studies also provide in vivo evidence that CMZ may also afford neuroprotection via anti-inflammatory pathways, as evidenced by a decrease in iNOS and arginase activities. Furthermore, these studies have also show evidence that angiogenesis (CD31) can be used as a diagnostic tool to assess neuroprotection / neurodegeneration.